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Phorbol ester induces desensitization of adenylate cyclase and
phosphorylation of the j8-adrenergic receptor in turkey erythrocytes
(tumor promoter/receptor regulation)
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Communicated by Elizabeth C. Miller, April 2, 1984
ABSTRACT Incubation of turkey erythrocytes with the
phorbol ester phorbol 12-myristate 13-acetate (PMA) results
in a dose- and time-dependent desensitization of isoproterenol-
stimulated adenylate cyclase activity. Compared to controls,
membranes from PMA-treated cells have an isoproterenol-
stimulated adenylate cyclase activity that is decreased 20%-
40%, with little effect on forskolin or fluoride activation of
adenylate cyclase. No change in .3-adrenergic receptor number
is observed after PMA treatment, indicating that the major
effect ofPMA is to uncouple receptor interactions with N., the
stimulatory guanine nucleotide regulatory protein of adenylate
cyclase. Purification of .8-adrenergic receptors from 32P1-la-
beled turkey erythrocytes, incubated in the presence or ab-
sence of PMA, indicates that the phorbol ester is capable of
inducing a 3-fold increase in phosphorylation of the /-adre-
nergic receptor. The PMA effect is similar to the phosphoryl-
ation of the .3-adrenergic receptor during isoproterenol- and
dibutyryl cAMP-induced desensitization of adenylate cyclase
in turkey erythrocytes. The findings indicate that decreased
receptor-N, coupling is correlated with receptor phosphoryl-
ation and that phorbol esters can influence the responsiveness
of hormone-sensitive adenylate cyclase in certain cell types.
Phorbol esters, such as phorbol 12-myristate 13-acetate
(PMA), are well-known tumor promoting agents that induce
a variety of functional and biochemical changes in cells (1-
8). Several recent reports suggest that the high-affinity bind-
ing site for phorbol esters is the Ca2+/phospholipid-depen-
dent protein kinase C (9-11). Phorbol esters have also been
shown to influence several plasma membrane-associated
hormone receptor systems. For example, PMA treatment of
cells decreases the affinity of epidermal growth factor (12-
17) and insulin (18) for their respective receptors. Recently,
PMA was shown to stimulate the phosphorylation of insulin
and somatomedin C receptors (19).
PMA has been reported to induce a desensitization of iso-
proterenol-stimulated adenylate cyclase activity in C6 glio-
ma cells (20) and mouse skin and epidermis (21), although
the properties of the desensitization have not been charac-
terized. In this communication, we show that PMA induces
phosphorylation of -adrenergic receptors and uncoupling of
receptor activation of adenylate cyclase in turkey erythro-
cytes. The influence of phorbol esters on hormone-sensitive
adenylate cyclase and other cell-surface hormone receptors
may well be an important component in the action of these
compounds.
METHODS
PMA and Isoproterenol-Induced Desensitization of Turkey
Erythrfocytes. Fresh washed turkey erythrocytes in Eagle's
minimal essential medium containing 50 mM Hepes (pH 7.4)
were incubated 60 min at 370C and then treated with 4 uM
PMA or 1 ,uM isoproterenol for 30 min at 370C unless stated
otherwise in the figure legends. After chilling and washing,
the cells were resuspended in 2 vol of 5 mM Tris HCI/3 mM
MgCl2, pH 8.0, and broken by nitrogen cavitation (22).
Membranes isolated from the 15%-40% sucrose interface of
sucrose step gradients (100,000 x g; 20 min) were washed
twice (35,000 x g; 30 min) in the gradient buffer minus su-
crose (20 mM Tris HCl/2 mM EDTA/10 mM MgCl2/100
mM NaCl, pH 8) and stored at -70°C in the same buffer.
32P-Labeling of Turkey Erythrocyte P-Adrenergic Recep-
tor. Turkey erythrocytes were labeled with 32p;, using a
modification of the procedure of Alper et al. (23, 24). Turkey
erythrocytes (5-8 ml) were incubated 19 hr at 35-37°C in 25
ml of buffer containing 150 mM NaCl/2.5 mM KCl/11.1 mM
glucose/10 mM Hepes/0.05 mM CaCl2/0.1 mM MgCI2, pH
7.4/32p; (0.5-1.0 mCi/ml; 1 Ci = 37 GBq). In control experi-
ments, radioactivity was omitted and 0.2 ,uM NaH2PO4 was
added. PMA (10 ,M) or isoproterenol (1 ,aM) was then add-
ed and incubation continued for 30 min at 37°C. Subsequent
procedures were carried out at 4°C. The cells were then
washed 3 times with 30 vol of buffer (150 mM NaCl/2.5 mM
KCl/11.1 mM glucose/10 mM Hepes, pH 7.4) followed by a
20-min incubation in 30 vol of lysis buffer (5 MM Tris HCl/2
mM EDTA/5 mM MgCl2, pH 7.4) containing sodium fluo-
ride (1 mM), aprotinin (0.2 units/ml), and phenylmethylsul-
fonyl fluoride (100 ,ug/ml). After washing twice with 30 vol
of lysis buffer containing sodium fluoride, the nucleated
ghosts were extracted with 2% digitonin for 60 min at 4°C. R-
Adrenergic receptor was purified 1,000- tq 4,000-fold by al-
prenolol Sepharose chromatography in digitonin as de-
scribed (22), using bovine serum albumin-treated alprenolol
Sepharose; all manipulations were carried out at 4°C.
Other Procedures. Photoaffinity labeling using [125I]iodo-
azidobenzylpindolol (IABP), [1251]iodocyanopindolol
(ICYP) binding assays and NaDodSO4/polyacrylamide gel
electrophoresis and autoradiography were done as described
(22). Standard concentrations of [125I]IABP and [125I]ICYP
used were 1.5 nM and 0.2 nM, respectively. Adenylate cy-
clase assays were dQne as described (25).
Materials. 32p; (9000 Ci/mmol) and [125I]ICYP were
from New England Nuclear. [1251]IABP and digitonin were
prepared as described (22). PMA was obtained from P-L
Biochemicals.
RESULTS
Fig. 1 shows a time course of isoproterenol-stimulated ade-
nylate cyclase activity in the presence of GTP, using mem-
branes prepared from control turkey erythrocytes and after
Abbreviations: ICYP, iodocyanopindolol; IABP, iodoazidobenzyl-
pindolol; PMA, phorbol 12-myristate 13-acetate; N,, stimula-
tory guanine nucleotide regulatory protein of adenylate cyclase;
GTP[S], guanosine 5'-[y-thiol-triphosphate.
tPresent address: Department of Physiology and Biophysics, Uni-
versity of Iowa, Iowa City, IA 52242.
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FIG. 1. Time course of isoproterenol-stimulated adenylate cy-
clase activity. Membranes prepared from control (e) turkey erythro-
cytes or after a 30-min incubation of cells with either 10 ,M isopro-
terenol (n) or 25 ,g/ml PMA (A) were used to measure adenylate
cyclase activity in the presence of 20 AM GTP in the presence (solid
lines) or absence (broken line) of 10 AM isoproterenol. Values repre-
sent the mean of duplicate determinations, which varied by <5%.
incubation with PMA or isoproterenol. After a 30-min incu-
bation with either PMA or isoproterenol, there is a signifi-
cant desensitization of agonist-stimulated adenylate cyclase
activity. The approximate 50% decrease in adenylate cyclase
stimulation in membranes prepared from isoproterenol-treat-
ed turkey erythrocytes is similar to that reported by workers
in our laboratory (25) and others (26, 27) for avian erythro-
cytes. Exposure of turkey erythrocytes to PMA for 30 min
resulted in an approximate 30% decrease in isoproterenol-
stimulated adenylate cyclase activity. The degree of desensi-
tization after PMA treatment was generally about one-half
that observed with isoproterenol treatment of the turkey
erythrocytes. Table 1 confirms the desensitization of isopro-
terenol-stimulated adenylate cyclase activity after PMA or
isoproterenol treatment of turkey erythrocytes. After pre-
treatment of cells with either isoproterenol or PMA, the cy-
clase activity in isolated membranes in the presence of iso-
proterenol and GTP is significantly decreased, while the iso-
proterenol-stimulated activity in the presence of guanosine
5'--y-thio]-triphosphate (GTP[S]) is less affected. The ability
of forskolin or fluoride to activate adenylate cyclase is
slightly, but reproducibly, diminished in membranes pre-
pared from cells incubated with isoproterenol or PMA. This
heterologous-type desensitization is somewhat less than re-
ported by others (26, 27), and it is probably due in part to our
relatively short incubation intervals of cells with isoprotere-
nol or PMA. Our data show that a 30-min exposure of intact
turkey erythrocytes to isoproterenol or PMA has the pri-
mary effect of uncoupling ,¢adrenergic receptor stimulation
of adenylate cyclase activity. No effect of isoproterenol or
PMA was observed on receptor number (not shown).
Fig. 2 shows the time course and dose dependency of the
PMA-induced desensitization of isoproterenol-stimulated
adenylate cyclase activity. PMA at a relatively high concen-
tration (4 AM) induces a maximal desensitization of isopro-
terenol-stimulated adenylate cyclase activity within 20 min
at 370C with an apparent t112 of 7-8 min. A similar time
course for isoproterenol-induced desensitization is also ob-
served (not shown). Exposure of erythrocytes to PMA for 30
min at 370C induces maximal desensitization at 1-4 AM PMA
with a half-maximal effect at =100 nM PMA. The dose-re-
sponse relationship shown here for PMA-induced desensiti-
zation of isoproterenol-stimulated adenylate cyclase activity
is similar to that for PMA-induced phosphorylation of a Mr
40,000 protein during platelet activation (9). PMA (1 AM)
added directly to control membranes had no effect on ade-
nylate cyclase activity in the presence of isoproterenol and
GTP or fluoride, indicating that PMA was not in some way
nonspecifically interacting with adenylate cyclase compo-
nents to decrease agonist stimulation (not shown). Further-
more, the non-tumor-promoting compound 4a-phorbol did
not induce desensitization of hormone-sensitive adenylate
cyclase at concentrations as high as 10 ,M (not shown).
Our findings indicate that PMA is capable of decreasing
the ability of isoproterenol to activate adenylate cyclase.
Fig. 3 shows that the presence of 4 ,M PMA during a 30-min
treatment of turkey erythrocytes with isoproterenol does not
significantly alter the EC50 for isoproterenol-induced desen-
sitization of adenylate cyclase. The maximal desensitization
observed with 0.01-10 AM isoproterenol was always greater
in the presence of PMA. The difference, however, was con-
sistently less than additive, suggesting that the effects of
PMA and isoproterenol are different, but may be affecting a
common component of the adenylate cyclase system. Work
done in several laboratories (25-29) indicates the initial
event in agonist-induced desensitization is an uncoupling of
f3-adrenergic receptor interactions with the stimulatory gua-
nine nucleotide regulatory protein of adenylate cyclase (Nj).
Stadel et al. (30) have also recently demonstrated that iso-
proterenol-induced desensitization of turkey erythrocytes
results in an increased phosphorylation of the -adrenergic
receptor. These findings suggest that regulation of coupling
between receptor and N, could be regulated by phosphoryl-
ation-dephosphorylation mechanisms. Furthermore, a high-
affinity receptor for phorbol esters has recently been shown
to be the Ca2+/phospholipid-dependent protein kinase C
(9-11), suggesting that PMA-induced desensitization may in-
volve a phosphorylation reaction.
Evidence that the ,3-adrenergic receptor is phosphorylated
in response to PMA is shown in Fig. 4. Turkey erythrocytes
labeled with 32p, were exposed to PMA or isoproterenol and
the receptors were purified on alprenolol-Sepharose. After
gel filtration to remove alprenolol, the amount of ,3-adrener-
gic receptor was quantitated and equal amounts of specific
[1251]ICYP binding activity were loaded on NaDodSO4 gels
Table 1. Adenylate cyclase activity in membranes prepared from turkey erythrocytes incubated in
the presence or absence of isoproterenol or PMA
Assay Control, Isoproterenol, PMA,
addition pmol of cAMP mg-'-min-' pmol of cAMP mg-'-min-' pmol of cAMP mg-'-min-'
GTP 2.4 ± 0.45 1.6 ± 0.71 1.8 ± 0.33
ISO/GTP 21 ± 0.5 12 ± 1.1 (42.9) 15 ± 0.6 (28.6)
ISO/GTP[S] 220 ± 7.7 164 ± 10.6 (25.5) 196 ± 10.0 (10.9)
Forskolin 36 ± 0.2 34 ± 1.0 (5.6) 34 ± 1.0 (5.6)
Fluoride 177 ± 2.5 173 ± 8.3 (2.3) 164 ± 6.5 (7.3)
Turkey erythrocytes were treated for 30 min at 370C with 100 AuM isoproterenol (ISO) or PMA (25
Ag/ml), then washed, and membranes were isolated. Adenylate cyclase activity was then measured in
the presence of various combinations of 10 ,M GTP, 10 ,uM ISO, 100 AM GTP[S], 10 mM fluoride, or
100 ,uM forskolin. Assays were for 20 min at 30'C. Values represent mean ± SD (n = 3). Numbers in
parentheses represent the percentage difference in adenylate cyclase activity of isoproterenol or PMA-
treated preparations relative to control membranes.
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FIG. 2. (A) Time course of PMA-induced desensitization. Tur-
key erythrocytes were incubated 60 min at 370C and then treated
with 4 AuM PMA for the times shown. The cells were then chilled 15
min in ice prior to centrifugation and preparation of membranes. The
adenylate cyclase activity of membranes from control cells treated
with vehicle only (0.025% ethanol) was 7.0 ± 0.22 pmol of cAMP
mg-' min-'. (B) Dose dependence of PMA-induced desensitiza-
tion. Turkey erythrocytes were incubated as in A and then treated
for 30 min at 370C with 0.1, 1, 4, or 40 ILM PMA. Membranes were
then isolated and assayed for adenylate cyclase activity. Activity of
membranes from control cells was 6.5 ± 0.17 pmol of cAMP
mg-' -min- 1. Adenylate cyclase activity in A and B represents activ-
ity assayed in the presence of 20 utM (-)-isoproterenol and 20 IxM
GTP and is expressed relative to that of control membranes.
and electrophoresed. Autoradiograms of the NaDodSO4
gels, containing equal amounts of specific receptor binding,
show a significant increase in the phosphorylation of a Mr
39,000 peptide in response to both PMA and isoproterenol.
The Mr 39,000 peptide corresponds to the same Mr as the
major form of the /3-adrenergic receptor purified from turkey
erythrocytes (22, 30, 31). A second receptor peptide of Mr
52,000, which is variable in amount in different preparations
(22, 30, 31), was not abundant after purification of the /3-
adrenergic receptor in these two experiments. Thus, both
PMA and isoproterenol induce desensitization of adenylate
cyclase and phosphorylation of the Mr 39,000 /3-adrenergic
receptor peptide. Quantitation of the receptor phosphoryl-
ation in response to PMA and isoproterenol is shown in Ta-
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FIG. 3. Dose dependence of isoproterenol-induced desensitiza-
tion in the presence or absence of PMA. Turkey erythrocytes were
incubated without additions for 60 min at 370C. The cells were then
treated for an additional 30 min at 370C with 0, 0.01, 0.03, 0.1, 0.3, or
10 uiM (-)-isoproterenol either in the absence (-) or presence (a) of
4 gM PMA. Membranes were then isolated and assayed for adenyl-
ate cyclase activity. Activity in the presence of 20 /M (-)-isoproter-
enol and 20 tkM GTP is shown expressed relative to control activity
(10.8 ± 0.11 pmol of cAMP mg-1'min').
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FIG. 4. Autoradiograms of NaDodSO4/10% polyacrylamide gels
of 32P-labeled preparations containing f-adrenergic receptors par-
tially purified by alprenolol-Sepharose chromatography. Prepara-
tions were from 32P-labeled turkey erythrocytes treated for 30 min at
370C with vehicle only (control, lanes 1, 6, and 8), 10 A±M PMA
(lanes 3, 4, and 7), or 1 ,uM (-)-isoproterenol (lanes 2 and 5). Sam-
ples in lanes 1-6 represent
-200-gl aliquots of 2.8 ml G-50 void
volume fractions containing peak ['25I]ICYP binding activity and
represent 0.7 fmol of 3-adrenergic receptor per lane. Samples in lane
7 (PMA-treated) and lane 8 (control) represent 200-/.l aliquots of 3.6-
ml eluates from alprenolol-Sepharose taken prior to G-50 column
chromatography. The results of two separate experiments are
shown (exp. 1, lanes 1-3; exp. 2, lanes 4-8). Exposure of autoradio-
graphs was for 8-10 days. The bromophenol blue tracking dye was
allowed to run just off the bottom of the gels.
ble 2. Densitometry of the Mr 39,000 band in lanes 1-3 and
lanes 4-6 of Fig. 4, in which the amount of receptor loaded
on each lane was the same as determined by [125I]ICYP bind-
ing, indicates an approximately 2- to 3-fold increase in the
phosphorylation of the f3-adrenergic receptor peptide by ei-
ther agent.
Evidence that the Mr 39,000 peptide whose phosphoryl-
ation is enhanced by both PMA and isoproterenol, is in fact
the f-adrenergic receptor, is shown in Fig. SA. It has been
previously demonstrated that the f3-adrenergic receptor pho-
toaffinity probe [1251]IABP specifically labels a predominant
Mr 39,000 peptide and a Mr 52,000 peptide of low abundance
in turkey erythrocyte membranes and with the alprenolol-
Sepharose purified receptor (22). Photolabeling of both pep-
tides is specifically blocked by propranolol. Similar results
have been reported by Stadel et al. (30) using [1251]iodoazi-
docarazolol. Lanes 1 and 2 of Fig. SA show the [1251]IABP
photolabeling profile of a partially purified B-adrenergic re-
ceptor preparation in the absence (lane 2) and presence (lane
1) of propranolol. The predominant Mr 39,000 and less abun-
dant Mr 52,000 receptor peptides are specifically labeled by
[1251]IABP, and the labeling is blocked by propranolol.
When 32P-labeled cells are used as a source of f3-adrenergic
receptor, alprenolol specifically elutes the Mr 39,000 peptide
from an alprenolol-Sepharose column (Fig. SA, lane 3). Sub-
stitution of an equimolar concentration of NaCl for alpreno-
lol in the elution buffer results in failure to elute this band
(lane 4). The 32P-labeled Mr 39,000 band eluted by alprenolol
(lane 3) can be specifically photolabeled with [' IJIABP
(lane 5). The photolabeling is specifically blocked by propan-
olol (lane 6). In this preparation, there is phosphorylation to
a small degree of the Mr 52,000 peptide (lane 3), which is also
photolabeled with [1251]IABP (lane 5). The remaining label in
the receptor bands in lane 6, which is [1251]IABP photolabel-
ing in the presence of propranolol, is primarily due to the 32p
incorporated into the peptides as observed in lane 3. Thus,
the bands specifically eluted from the affinity column by al-
prenolol are specifically photolabeled using [125I]IABP and
represent the 3-adrenergic receptor binding protein.
Further evidence that the phosphorylated Mr 39,000 and
Mr 52,000 bands are the 8-adrenergic receptor is shown in
Fig. 5B. ,3-Adrenergic receptors from 32P-labeled turkey
erythrocytes were purified on an alprenolol-Sepharose col-
umn. The fraction eluted from the affinity column by alpren-
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Table 2. 32p phosphorus content of M, 39,000 (3-adrenergic
receptor peptide from PMA- or isoproterenol-treated
turkey erythrocytes relative to control
Exp. 1 Exp. 2
Control 1.0 1.0
Isoproterenol 3.3 1.6
PMA 3.2 2.2
f-Adrenergic receptors were partially purified by alprenolol-
Sepharose chromatography from 32P-labeled turkey erythrocytes
treated for 30 min with either PMA (10 MzM), isoproterenol (1 gM),
or vehicle only (control). p-Receptor content of the Mr 39,000 band
was estimated as the A-receptor content of the samples loaded onto
NaDodSO4/10% polyacrylamide gels based on specific [251I]ICYP
binding, and ranged from 0.4 to 1.4 fmol of p-receptor per lane.
Phosphorus content of the M, 39,000 band was estimated by densi-
tometry of 32P autoradiographs developed after 8-10 days and is ex-
pressed in arbitrary units. For each condition, 32p phosphorus con-
tent per unit of p-receptor was then calculated and is expressed rela-
tive to the control.
olol was chromatographed on a Sephadex G-50 column to
remove the alprenolol, and void volume fractions were as-
sayed for specific [1251]ICYP binding or run on NaDodSO4
gels and autoradiographed. Specific [1251]ICYP binding cor-
responds to 0.1, 1.3, 1.8, and 1.0 fmol (lanes 1-4, respective-
ly). There is a positive correlation of ['251]ICYP binding and
purification of the phosphorylated Mr 39,000 and Mr 52,000
peptides. By several criteria, including specific elution by
alprenolol, photolabeling of the phosphorylated peptides an-
alyzed on NaDodSO4 gels (Fig. 5A), and specific binding
with [1251]-ICYP in fractions eluted from a gel filtration col-
umn (Fig. SB) indicate, that the phosphorylated peptides are
,3adrenergic receptor ligand binding proteins.
DISCUSSION
Our findings demonstrate two effects of PMA: (i) desensiti-
zation of isoproterenol activation of adenylate cyclase and
(ii) increased phosphorylation of the ,3-adrenergic receptor.
The results also support the findings of Stadel et al. (30) that
isoproterenol-induced desensitization of adenylate cyclase
in turkey erythrocytes results in phosphorylation of the 1-
adrenergic receptor. Phorbol ester-induced effects on the
hormone-sensitive adenylate cyclase system may be a gener-
al phenomenon. PMA induces desensitization of hormone-
stimulated adenylate cyclase in turkey erythrocytes (this re-
port), C6 glioma (20), and mouse skin and epidermis (21). We
have preliminary evidence that phorbol esters alter the regu-
lation of hormone-sensitive adenylate cyclase in A431 hu-
man carcinoma cells (unpublished data).
The PMA-induced desensitization that we observe in tur-
key erythrocytes is similar in magnitude to the desensitiza-
tion observed with dibutyryl cAMP (26). However, our stud-
ies in turkey erythrocytes and those of others in different cell
types (32) suggest no major or consistent effect of PMA on
increasing cAMP levels. We have also found that the 3-ad-
renergic receptor in membranes or purified in a soluble or
liposome reconstituted form is a poor substrate for the puri-
fied catalytic subunit of cAMP-dependent protein kinase
from bovine heart (unpublished observation). The work of
Stadel et al. (30) also suggested the ,3adrenergic receptor is
a poor substrate for cAMP-dependent protein kinase. Using
a genetic approach, two other independent lines of evidence
suggest that activation of cAMP-dependent protein kinase
does not have to occur during desensitization. Shear et al.
(33), using a cAMP-dependent protein kinase-deficient mu-
tant (kin-) of S49 mouse lymphoma cells, demonstrated that
isoproterenol-induced desensitization is essentially identical
in the kin- mutants compared to wild-type cells. Green and
Clark (34), using membrane reconstitution procedures, also
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FIG. 5. Autoradiograph of NaDodSO4/10% polyacrylamide gel
of 32P-labeled and [125I]IABP photoaffinity-labeled partially purified
P-adrenergic receptor. (A) Turkey erythrocytes labeled with 32p
were treated with 1 MM isoproterenol for 30 min at 370C. A digitonin
extract of washed nucleated ghosts was incubated with alprenolol-
Sepharose. After washing, the affinity resin was divided into two
equal portions. One portion was eluted with 200 MM alprenolol in 0.3
M NaCl; the other portion was eluted with 200 MM NaCl added to
the 0.3 M NaCl containing wash buffer. Both eluates were chroma-
tographed on Sephadex G-50 columns and [1251]ICYP binding was
assayed throughout the void volume fractions. Alprenolol specifical-
ly eluted the receptor compared to the control salt elution. Aliquots
from peak fractions electrophoresed on NaDodSO4/l0% polyacryl-
amide gels are shown in A for elution by alprenolol (lane 3) or con-
trol (lane 4). A Mr 39,000 band and a less prominent Mr 52,000
band are detectable in lane 3. A control partially purified P-adrener-
gic receptor preparation [1251]IABP photolabeled in the absence
(lane 2) or presence (lane 1) of 10 MM propranolol is shown for com-
parison. [1251]IABP photolabeling of the alprenolol-eluted 32P-la-
beled preparation shown in lane 3 gives a similar specific labeling
pattern compared to control in the absence (lane 5) or presence (lane
6) of 10 MM propranolol. The remaining label at Mr 39,000 and Mr
52,000 in lane 6 is due to 32P-labeling in the bands. (B) Lanes 1-4 are
the G-50 void volume fractions of the 32P-labeled p-adrenergic re-
ceptor preparation eluted from alprenolol-Sepharose using 200 AM
alprenolol. Based on [1251]ICYP binding, 0.1, 1.3, 1.8, and 1.0 fmol
of padrenergic receptor was loaded on lanes 1-4, respectively. Ex-
posure of autoradiographs was for 6 days (A) and 8 days (B).
demonstrated isoproterenol-induced desensitization in cyc-
S49 mutants, which lack a functional N, protein and do not
activate adenylate cyclase in response to isoproterenol.
How then could desensitization of hormone-sensitive ade-
nylate cyclase occur in the turkey erythrocyte? It is tempting
to hypothesize that protein kinase C is involved; however,
our data do not demonstrate that protein kinase C phosphor-
ylates the ,B-adrenergic receptor. Certainly, other kinases or
phosphatases may be involved in the change in phosphoryl-
ation state of the receptor. The correlation between phos-
phorylation of the /3-adrenergic receptor and desensitization
by PMA, isoproterenol, and dibutyryl cAMP is compelling
evidence to hypothesize that this is an important mechanism
to regulate receptor-N, coupling. Phosphorylation of the re-
ceptor at two different sites, depending on agonist occupan-
cy and the resulting conformation of the receptor, could ex-
plain the partial desensitization observed with PMA com-
pared to isoproterenol.
Agonist-induced desensitization of adenylate cyclase is
admittedly different in turkey erythrocytes compared to
many other cell types. Most notably is the failure of P-adren-
ergic receptors to be internalized by turkey erythrocytes
during desensitization. In other cell types, internalization of
receptors appears to be a component of the desensitization
process for hormone-sensitive adenylate cyclase. Since
phosphorylation of the ,B-adrenergic receptor has been ob-
served only in the turkey erythrocyte, the question that
arises is whether receptor phosphorylation is unique to the
avian erythrocyte. We are not aware of any reports that di-
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rectly address this question. There are several studies that
may bear on this question indirectly. Birnbaumer and co-
workers (35, 36) and others (37, 38) have described isolated
membrane systems in which agonist-induced uncoupling of
receptor-N, interactions could be observed. The decreased
efficiency of receptor-N, coupling usually required ATP,
was receptor mediated, and imidodiphosphate analogs of
ATP could not induce the uncoupling. The data suggest that
receptor-N, uncoupling might be mediated by phosphoryl-
ation, and furthermore, cAMP is not required. In many re-
spects, the degree of agonist-induced uncoupling of recep-
tor-N, interactions in these mammalian membrane prepara-
tions is similar to the desensitization phenomenon observed
in avian erythrocytes. Therefore, phosphorylation of recep-
tors could conceivably be an early step in agonist-induced
desensitization of adenylate cyclase in many cell types. En-
docytosis of the receptor could result in rapid dephosphoryl-
ation due to phosphatases present in the cytoplasm of the
cell, making detection of phosphorylated receptor difficult.
The ability to purify components and reconstitute receptor-
Ns interactions in liposomes (22, 39, 40) or cells (41, 42)
should allow us to develop in vitro systems to directly ad-
dress the questions of phosphorylation and the regulation of
receptor-Ns interactions.
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